Home » Genmab Signs Cancer Drug Deal Worth Up to $1.1B

Genmab Signs Cancer Drug Deal Worth Up to $1.1B

August 30, 2012

Danish biopharmaceutical company Genmab A/S Thursday said it has granted Janssen Biotech Inc. an exclusive global license to develop and commercialize its Daratumumab treatment for multiple myeloma, a form of cancer found in bone marrow, in a deal that could be worth up to $1.1 billion.
MarketWatch

09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
17Feb
Effective Auditing for Manufacturing Quality
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Genmab Signs Cancer Drug Deal Worth Up to $1.1B

Upcoming Events

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Effective Auditing for Manufacturing Quality

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

FDA Gives MeiraGTx’s Achromatopsia Therapy Fast-Track Status

TGA Investigates COVID-19 Tests and Emerging Variants

The Revised ICH E8: A Guide to New Clinical Trial Requirements